Contract Research & Services
Clinical Trials

Clinical Trials News

View news from other Pharmaceutical sectors:
61-75 of 4306 results
BMS’ Opdivo-Yervoy combo succeeds in phase 3 NSCLC trial
By PBR Staff Writer
Bristol-Myers Squibb (BMS) said that the combination of its immuno-oncology drugs Opdivo (nivolumab) and Yervoy (ipilimumab) demonstrated superior progression-free survival (PFS) in first-line non-small cell lung cancer (NSCLC) patients with high tumor mutation burden (TMB) in a phase 3 trial.
Contract Research & Services > Clinical Trials > News
PharmAbcine, Merck to assess TTAC-0001 in combination with Keytruda in recurrent rlioblastoma and breast cancer
PharmAbcine has signed a collaborative agreement with Merck (MSD) to evaluate its anti-VEGFR2 mAb, TTAC-0001, in combination with MSD’s anti-PD-1 (programmed death receptor-1) therapy, Keytruda (pembrolizumab), in patients with recurrent glioblastoma multiforme (rGBM) and metastatic triple-negative breast cancer (TNBC).
Contract Research & Services > Clinical Trials > News
Syndax partners with AstraZeneca for immuno-oncology clinical trials
Syndax Pharmaceuticals and AstraZeneca have agreed to evaluate the safety and efficacy of AstraZeneca's durvalumab in combination with the former's SNDX-6352 across a variety of solid tumors.
Contract Research & Services > Clinical Trials > News
Sage Therapeutics' SAGE-217 shows positive effect in phase 1/2 insomnia trial
Sage Therapeutics’ sleep disorder drug SAGE-217 has yielded positive results from a phase 1/2 trial in healthy adult volunteers using a 5-hour phase advance model of insomnia using polysomnography.
Contract Research & Services > Clinical Trials > News
SillaJen initiates phase 1/2 trial of Pexa-Vec in metastatic colon cancer
SillaJen has initiated a phase 1/2 clinical trial of pexastimogene devacirepvec (Pexa-Vec) in combination with checkpoint inhibitor therapy for the treatment of metastatic colon cancer.
Contract Research & Services > Clinical Trials > News
AstraZeneca’s PT010 triple combination therapy shows significant effect in COPD trial
AstraZeneca has reported top-line results from the Phase III KRONOS trial, which showed significant effect of PT010 triple combination therapy in chronic obstructive pulmonary disease (COPD).
Contract Research & Services > Clinical Trials > News
Alligator appoints Theradex Oncology as clinical CRO for ATOR-1015 phase I study
Alligator Bioscience has appointed Theradex Oncology has appointed as CRO for the planned phase I study of ATOR-1015 for the treatment of metastatic cancer.
Contract Research & Services > Clinical Trials > News
Rexgenero starts phase III program with REX-001 for CLI treatment
By PBR Staff Writer
UK-based regenerative medicine company Rexgenero has treated first patient in its phase III program with lead product REX-001, a cell therapy for the treatment of Critical Limb Ischemia (CLI)
Contract Research & Services > Clinical Trials > News
Alzheimer’s drug Solanezumab fails to slow cognitive decline in clinical study
By PBR Staff Writer
A study has demonstrated that Alzheimer’s drug, solanezumab, targeting amyloid plaques, did not significantly slow cognitive decline.
Contract Research & Services > Clinical Trials > News
Pfizer’s rituximab biosimilar succeeds in phase III follicular lymphoma trial
By PBR Staff Writer
Pfizer’s PF-05280586, a potential biosimilar to rituximab, has met its primary endpoint of overall response rate in a clinical trial of patients with CD20-positive follicular lymphoma and low tumor burden.
Contract Research & Services > Clinical Trials > News
SymBio begins phase 1 trial for treakisym in progressive solid tumors
SymBio Pharmaceuticals has launched a phase 1 study in Japan for oral Treakisym in patients with progressive solid tumors.
Contract Research & Services > Clinical Trials > News
ImmuPharma completes phase 3 trial of Lupus drug
ImmuPharma has completed its 52-week, randomised, double-blinded, phase 3 clinical trial of Lupuzor, its lead candidate for the potential breakthrough compound for Lupus.
Contract Research & Services > Clinical Trials > News
Merck’s Keytruda regimen succeeds in phase 3 NSCLC trial
By PBR Staff Writer
Merck’s Keytruda (pembrolizumab) in combination with pemetrexed (Alimta) plus platinum chemotherapy has significantly improved overall survival (OS) and progression-free survival (PFS) of certain type of lung cancer patients in a phase 3 trial.
Contract Research & Services > Clinical Trials > News
Allergy Therapeutics completes patient recruitment in PQ Birch phase III clinical trial
Allergy Therapeutics has completed recruitment of patients in the PQ Birch phase III clinical trial.
Contract Research & Services > Clinical Trials > News
BerGenBio meets first efficacy endpoint in phase II trial with selective AXL inhibitor BGB324 in NSCLC
BerGenBio announced that it met the first efficacy endpoint in the phase II clinical trial evaluating BGB324 (bemcentinib), a selective AXL inhibitor, in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC) who have progressed on an approved EGFR inhibitor.
Contract Research & Services > Clinical Trials > News
61-75 of 4306 results